These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 9367217)

  • 1. Solid-phase extraction and high-performance liquid chromatographic determination of tamoxifen and its major metabolites in breast tumour tissues.
    MacCallum J; Cummings J; Dixon JM; Miller WR
    J Chromatogr B Biomed Sci Appl; 1997 Sep; 698(1-2):269-75. PubMed ID: 9367217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Solid-phase extraction and high-performance liquid chromatographic determination of tamoxifen and its major metabolites in plasma.
    MacCallum J; Cummings J; Dixon JM; Miller WR
    J Chromatogr B Biomed Appl; 1996 Apr; 678(2):317-23. PubMed ID: 8738037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Volumetric Absorptive Microsampling as a New Biosampling Tool for Monitoring of Tamoxifen, Endoxifen, 4-OH Tamoxifen and N-Desmethyltamoxifen in Breast Cancer Patients.
    Maggadani BP; Harmita ; Haryono SJ; Rinaldi MR; Harahap Y
    Drug Des Devel Ther; 2021; 15():2417-2430. PubMed ID: 34113081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumours.
    MacCallum J; Cummings J; Dixon JM; Miller WR
    Br J Cancer; 2000 May; 82(10):1629-35. PubMed ID: 10817496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ultra-high performance liquid chromatography tandem mass spectrometric method for the determination of tamoxifen, N-desmethyltamoxifen, 4-hydroxytamoxifen and endoxifen in dried blood spots--development, validation and clinical application during breast cancer adjuvant therapy.
    Antunes MV; Raymundo S; de Oliveira V; Staudt DE; Gössling G; Peteffi GP; Biazús JV; Cavalheiro JA; Tre-Hardy M; Capron A; Haufroid V; Wallemacq P; Schwartsmann G; Linden R
    Talanta; 2015 Jan; 132():775-84. PubMed ID: 25476377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing high-performance liquid chromatography method with fluorescence detection for quantification of tamoxifen and two metabolites in human plasma: application to a clinical study.
    Zhu YB; Zhang Q; Zou JJ; Yu CX; Xiao DW
    J Pharm Biomed Anal; 2008 Jan; 46(2):349-55. PubMed ID: 18037598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitive HPLC-PDA determination of tamoxifen and its metabolites N-desmethyltamoxifen, 4-hydroxytamoxifen and endoxifen in human plasma.
    Antunes MV; Rosa DD; Viana Tdos S; Andreolla H; Fontanive TO; Linden R
    J Pharm Biomed Anal; 2013 Mar; 76():13-20. PubMed ID: 23291438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantification of tamoxifen and three metabolites in plasma by high-performance liquid chromatography with fluorescence detection: application to a clinical trial.
    Lee KH; Ward BA; Desta Z; Flockhart DA; Jones DR
    J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Jul; 791(1-2):245-53. PubMed ID: 12798184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An ultra performance liquid chromatography-tandem MS assay for tamoxifen metabolites profiling in plasma: first evidence of 4'-hydroxylated metabolites in breast cancer patients.
    Dahmane E; Mercier T; Zanolari B; Cruchon S; Guignard N; Buclin T; Leyvraz S; Zaman K; Csajka C; Decosterd LA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Dec; 878(32):3402-14. PubMed ID: 21094101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of CYP2D6 and CYP3A4 Phenotypes, Drug Interactions, and Vitamin D Status on Tamoxifen Biotransformation.
    Antunes MV; Timm TA; de Oliveira V; Staudt DE; Raymundo S; Gössling G; Biazús JV; Cavalheiro JA; Rosa DD; Wallemacq P; Haufroid V; Linden R; Schwartsmann G
    Ther Drug Monit; 2015 Dec; 37(6):733-44. PubMed ID: 25853922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific high-performance liquid chromatographic analysis of tamoxifen and its major metabolites by "on-line" extraction and post-column photochemical reaction.
    Kikuta C; Schmid R
    J Pharm Biomed Anal; 1989; 7(3):329-37. PubMed ID: 2488634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On-line high-performance liquid chromatographic-electrospray ionization mass spectrometric method for the study of tamoxifen metabolism.
    Jones RM; Yuan ZX; Lamb JH; Lim CK
    J Chromatogr A; 1996 Jan; 722(1-2):249-55. PubMed ID: 9019299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimised separation of E- and Z- isomers of tamoxifen, and its principal metabolites using reversed-phase high performance liquid chromatography.
    Manns JE; Hanks S; Brown JE
    J Pharm Biomed Anal; 1998 Jan; 16(5):847-52. PubMed ID: 9535197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aging may be associated with concentrations of tamoxifen and its metabolites in breast cancer patients.
    Sheth HR; Lord G; Tkaczuk K; Danton M; Lewis LM; Langenberg P; Lim CK; Flaws JA
    J Womens Health (Larchmt); 2003 Oct; 12(8):799-808. PubMed ID: 14588130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigational study of tamoxifen phase I metabolites using chromatographic and spectroscopic analytical techniques.
    Teunissen SF; Rosing H; Seoane MD; Brunsveld L; Schellens JH; Schinkel AH; Beijnen JH
    J Pharm Biomed Anal; 2011 Jun; 55(3):518-26. PubMed ID: 21392921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of 2-methyl derivatives of tamoxifen in cell culture medium using high-performance liquid chromatography and electrochemical detection.
    Chamart S; Hanocq M; Helson M; Devleeschauwer N; Leclercq G
    J Chromatogr; 1989 Nov; 496(2):365-75. PubMed ID: 2613840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of tamoxifen (TAM) and TAM metabolite concentrations with self-reported side effects of TAM in women with breast cancer.
    Gallicchio L; Lord G; Tkaczuk K; Danton M; Lewis LM; Lim CK; Flaws JA
    Breast Cancer Res Treat; 2004 May; 85(1):89-97. PubMed ID: 15039600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence that the catechol 3,4-Dihydroxytamoxifen is a proximate intermediate to the reactive species binding covalently to proteins.
    Dehal SS; Kupfer D
    Cancer Res; 1996 Mar; 56(6):1283-90. PubMed ID: 8640815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of tamoxifen and its main metabolites in plasma samples from breast cancer patients by micellar liquid chromatography.
    Peris-Vicente J; Ochoa-Aranda E; Bose D; Esteve-Romero J
    Talanta; 2015 Jan; 131():535-40. PubMed ID: 25281137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a high-performance liquid chromatography method with fluorescence detection for the routine quantification of tamoxifen, endoxifen and 4-hydroxytamoxifen in plasma from breast cancer patients.
    Rangel-Méndez JA; Graniel-Sabido MJ; Sánchez-Cruz JF; Moo-Puc R
    Biomed Chromatogr; 2019 Apr; 33(4):e4462. PubMed ID: 30536934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.